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Mastitis causes significant economic losses to the dairy industry,
with annual costs worldwide estimated at $35 bill ion
(Wellenberg et al., 2002). For over 50 years, the practice of
treating all udder quarters with a long-acting antibiotic at
drying-off (dry cow therapy, DCT) has been an important part
of mastitis treatment and prevention on dairy farms. DCT has
been hugely successful in curing many existing subclinical
infections and also offers short-term protection against new
intramammary infections (IMIs) during the early dry period.
Public concerns over the widespread prophylactic use of
antibiotics, coupled with an increasing interest in organic
farming,  have led to a search for alternatives to DCT for the
prevention of intramammary infections.
The increased susceptibility of mammary gland to new IMIs
during the early dry period is believed to be mainly due to
delays in the formation of a complete keratin plug in the streak
canal in the early dry period (Williamson et al., 1995). This can
be overcome through the application of an internal teat seal at
drying-off (reviewed in Crispie et al., 2004a). 
Teat seal (Boviseal, Bimeda, Cross VetPharm Group Ltd.,
Dublin, Ireland) is a non-antibiotic intramammary dry cow
product currently sold in many countries worldwide (Orbeseal,
Pfizer Animal Health). It is a viscous formulation that, when
infused into the teat canal and the teat sinus, provides a physical
barrier to invasion by mastitis-causing pathogens. The
formulation is primarily comprised of bismuth subnitrate (65%)
and liquid paraffin and is presented in a syringe for
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CMT California Mastitis Test
DCT dry cow therapy
DWP demineralised whey protein
IMI intramammary infection
RAPD random amplification of polymorphic DNA
SCC somatic cell count
TYG-L solubilised preparation of lacticin TYG
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intramammary application. Infusion of teat seal without an
antibiotic has been shown to be as effective as a long-acting
antibiotic in preventing new intramammary infections during
the dry period in cows which were infection-free and had
somatic cell counts (SCC) of less than 200,000 ml-1 at drying-
off (Woolford et al., 1998; Berry and Hillerton, 2002; Huxley
et al., 2002). 
Enhancement of teat seal formulations may be achieved using
non-antibiotic additives such as bacteriocins, potent proteins
produced by some bacteria that have the ability to kill other
microorganisms. The incorporation of a bacteriocin into the seal
may provide a method to prevent inadvertent contamination
during infusion, improving the safety of the product in the
hands of the untrained user. Lacticin 3147, a bacteriocin
produced by Lactococcus lactis DPC3147, has received much
attention in this regard. The purpose of this publication is to
summarise the data available on the efficacy of the teat seal in
combination with lacticin 3147 in the prevention of mastitis.
Why bacteriocins?
Bacteriocins were first proposed for treatment of mastitis when
the results of trials carried out by Taylor et al. (1949) indicated
that a single intramammary infusion of nisin, a bacteriocin
discovered in 1928 (Rogers and Whittier, 1928), was effective
in treating both streptococcal and staphylococcal infections.
Interest in the use of nisin as a therapeutic agent was renewed
when Broadbent et al. (1989) showed that nisin was inhibitory
to several Gram-positive, mastitis-causing pathogens. When
nisin, in combination with lysostaphin, was administered by
intramammary infusion, promising results were obtained with
cure rates of 66% for Staphylococcus aureus, 95% for Streptococcus
agalactiae, and 100% for Streptococcus uberis (Sears et al.,
1992a,b).
Lacticin is a bacteriocin produced by L. lactis DPC3147 (Rea
and Cogan, 1994; Ryan et al., 1998) that has a broad-spectrum
of activity against all Gram-positive bacteria, including many
mastitis-causing pathogens. The structure and mode of action of
lacticin has been documented (McAuliffe et al., 1998, 2000;
Martin et al., 2004). Ryan et al. (1998) examined the in vitro
sensitivity of 24 mastitic streptococcal and staphylococcal
isolates to lacticin 3147: all were inhibited, with the size of
zones of inhibition varying from ~ 10mm to 17mm (Ryan et al.,
1998). The bacteriocin appeared to be more potent against
streptococci than against staphylococci, with Streptococcus
dysgalactiae M the most sensitive strain tested. This was not
unexpected, as intramammary infections caused by S. aureus
have proved most difficult to cure with antibiotics, with the cure
rates reported as low as 25% (Pyörälä, 2002). L. lactis DPC3147
has been shown to inhibit representatives of the three main
RAPD-type staphylococcal isolates found in a study of Irish
farms (Fitzgerald et al., 1997; Twomey et al., 2000).
Efficacy of teat seal plus lacticin in the control of
streptococci
In an in vitro study, 35 seals containing lacticin were tested for
antimicrobial activity against Strep. dysgalactiae M: all 35 seals
displayed effective antimicrobial action against this pathogen
(Ryan et al., 1998, 1999).
The seal plus lacticin combination was infused into udder
quarters (Ryan et al., 1999) in order to assess the effects on
udder tissues. Clinical abnormality was not evident in any of the
treated quarters observed at milking twice each day over the
next five days. Overall, SCC trends were similar in the quarters
infused with either the seal alone or with the seal plus lacticin. 
The in vivo efficacy of teat seal plus lacticin against Strep.
dysgalactiae M was assessed in dry cows (Ryan et al., 1999). For
this purpose, 68 uninfected udder quarters were selected in 18
cows. After the last milking of the lactation, 33 quarters were
infused with seal and 35 with seal plus lacticin. Three days after
infusion, each of the 68 treated quarters was inoculated with 1.5
x 104 cfu Strep. dysgalactiae M. The cows were observed twice
daily (morning and evening) for clinical signs of mastitis. On the
last day of the experiment (eight days after inoculation), samples
of secretion were collected for microbiological analyses (Ryan et
al., 1999). The challenge organism caused clinical mastitis in 14
sealed quarters, in 12 (86%) of them by day two following the
bacterial challenge, and in two quarters infused with seal plus
lacticin, the first of which occurred on day 4 (Table 1). Thus,
there were significant differences both in the rate of new
infection (P<0.001) and in the intervals to each clinical event
(P<0.001).
When all remaining non-clinical quarters were sampled at the
end of the experiment, the challenge strain was recovered from
a further six quarters that had been infused with seal alone but
not from any of the non-clinical quarters that had been infused
with seal plus lacticin. Combining these results with the clinical
data, 20 sealed quarters and two quarters treated with seal plus
lacticin were either clinical or shedding the challenge strain
during the experiment (Table 1). Again, this difference was
significant (P<0.001). In total, seal plus lacticin protected 33
(94%) of the 35 teats against infection by the challenge
inoculum of Strep. dysgalactiae M (Ryan et al., 1999).
TABLE 1: Results of challenge with Streptococcus dysgalactiae M  (1.5 x 104 cfu) in udder quarters treated with either teat seal or teat
seal plus lacticin
Treatment Quarters(n) Clinical infections Strep. dysgalactiae M recovered from Total infections
non-clinical quarters (day 8)
Teat seal 33 14 (42.4%) 6 20 (60.6%)
Teat seal plus lacticin 35 2 (5.7%) 0 2 (5.7%)
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Efficacy of teat seal plus lacticin in the control of
Staphylococcus aureus
The in vivo efficacy of teat seal plus lacticin against S. aureus was
assessed in lactating cows (Twomey et al., 2000). After the
morning milking, two quarters in each cow were infused with
teat seal plus lacticin (4g; treatment group), and the two
remaining quarters in each cow were used as unsealed controls.
Two hours later the unsealed control quarters and the quarters
treated with seal plus lacticin were all inoculated with a
challenge inoculum of S. aureus DPC5246. The number of
bacteria in the challenge inoculum was altered in two
experiments. When a deliberate challenge with ~ 1.7 x 103 cfu
of S. aureus DPC5246 per quarter was used, a concentration of
~33,000AU lacticin per seal caused a significant reduction
(P<0.001) in the numbers of quarters shedding S. aureus
DPC5246. The S. aureus challenge survived in 19 (66%) of the
29 control quarters and in four (14%) of the 29 quarters infused
with teat seal plus lacticin (Table 2). In addition, the presence
of teat seal plus lacticin also resulted in a reduction in the  total
number of viable S. aureus DPC5246 cells recovered. When a
higher challenge inoculum level of ~ 6.8 x 103 cfu per quarter
was used, the teat seal plus lacticin formulation
(33,000AU/seal) was less successful in reducing the number of
quarters shedding S. aureus (Table 2).
While teat seals are not designed for the treatment of mastitis in
lactating cows, the data obtained in this trial demonstrated that
teat seal plus lacticin reduced both the number of quarters
shedding S. aureus and the numbers of bacteria shed. It was
speculated that if a similar formulation was developed as a dry
cow product, it should reduce the risk of mastitis considerably
(Twomey et al., 2000). 
Development of a milk-based lacticin formulation
The production of lacticin using a variety of food-based media
for the growth of L. lactis DPC3147 has been reported
(Morgan et al., 1999). Of the culture media evaluated, a 10%
reconstituted demineralised whey protein (DWP) was
considered the most suitable both in terms of the economics of
production and of culture performance. This substrate was used
to produce a lacticin-powder suitable for blending with teat seal.
Lacticin was concentrated from the clarified DWP fermentate,
freeze-dried and milled (Crispie et al., 2004b). A highly active
powder (lacticin DWP) containing ~1.6 x 106AU g-1 was
produced and blended with teat seal (0.1g of powder per 4g of
teat seal). The teat seal plus lacticin DWP formulation was filled
into intra-mammary syringes and sterilised by irradiation. The
effectiveness of this formulation in protecting against mastitis
pathogens in vivo was investigated. 
The teat seal plus lacticin DWP formulation was compared with
commercial teat seal in an experiment using 28 quarters in seven
cows selected on the basis of their udder health. Udder quarters
were randomised and two quarters in each cow were infused
with teat seal, while the remaining two quarters were infused
with teat seal plus lacticin DWP. Two hours later, an inoculum
of 1,340 cfu viable S. aureus DPC5246 was infused, via the
streak canal, into each of the 28 quarters; 18h later, the teat
seals were removed, foremilk samples were taken in an aseptic
manner and bacteria were enumerated (Figure 1). Significantly
fewer viable S. aureus DPC5246 cells were recovered from
quarters that had been infused with teat seal containing the
lacticin DWP than from quarters infused with commercial teat
seal (P<0.001).
Tissue tolerance studies
Three different experiments were performed to assess tissue
tolerance to the various lacticin 3147 preparations blended with
TABLE 2: The effectiveness of teat seal plus lacticin (32,768AU/4g teat seal) in eliminating Staphylococcus aureus DPC5246 
from artificially infected udder quarters of lactating cows compared with untreated controls. 
Shedding was evaluated 18h after inoculation of S. aureus
Treatment Inoculum (cfu per 0.1ml) Quarters inoculated (n) Quarters shedding S. aureus
Untreated 1.7 x 103 29 19 (66%)a
Teat seal + lacticin 29 4 (14%)b
Untreated 6.8 x 103 20 16 (80%)
Teat seal + lacticin 20 11 (55%)
a,b Values with different superscripts within an experiment are significant P <0.001.
FIGURE 1: Recovery of Staphylococcus aureus DPC5246 from milk 18
hours after experimental infection (1,340 cfu) of udder quarters
previously infused with either teat seal or teat seal plus DWP powder
(from Crispie et al., 2004b).
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teat seal. Teats of lactating cows whose foremilk was free of
pathogens and had less than 200,000 SCC ml-1 over three
consecutive milkings were selected for the three studies.
Approximately 8h after treatment, seals were removed and milk
samples were collected. Udder quarters were sampled for the
next ten consecutive milkings. Before and after infusion of the
test formulation, the SCC status was assessed by flow cytometry
using a Somacount 300 Somatic Cell Counter® (Bentley
Instruments Inc., USA). To overcome the problem of seal
particles interfering with the operation of the automatic somatic
cell counter, the California Mastitis Test (CMT) was used as a
subjective measure of SCC for the first three samplings after
infusion. CMT readings were scored on a scale of 1 to 5.
However, when plotting the mean CMT, the presence of clots
was also taken into consideration. Milk clots were scored on a
scale of 1 to 4 and this value was added to the CMT score (i.e.,
a sample with a CMT reading of 5 and a clot score of 2 was
given a final CMT reading of 7). 
Five cows were used in the first experiment. In each cow
individual udder quarters were treated with seal only, with seal
plus lacticin DWP, with a commercial antibiotic preparation
containing sodium cloxacillin (Orbenin QR, Pfizer Animal
Health, Ireland), or were left untreated. Quarters infused with
teat seal containing the lacticin DWP had higher somatic cell
counts than the untreated quarters or quarters infused with teat
seal alone. However, when the mean log SCC data from the
four samples pre-infusion and the final two samples post-
infusion were compared between treatments the differences
were not significant (P=0.352). Additionally, when the mean
log SCC post-infusion were compared, the differences between
the treatments were insignificant (P=0.078).
For the second experiment lacticin was prepared from a
synthetic medium TYG (lacticin TYG) in a similar manner to
the DWP powder, and was blended with teat seal. In this
experiment, individual udder quarters of five cows were treated
with seal, with seal plus lacticin DWP, with seal plus lacticin
TYG, or were left untreated. Quarters infused with seal plus
lacticin DWP or with lacticin TYG had elevated SCC values in
comparison with the controls, but there were no significant
differences between treatments in the mean log SCC post-
infusion (P=0.111). When the mean log SCC data from the
four samples pre-infusion and the final two samples post-
infusion were compared across treatments the differences were
not significant (P=0.331).
In the third experiment, two quarters in each of eight cows were
infused either with teat seal plus a solubilised preparation of
lacticin TYG (Lacticin TYG-L) or with seal alone; one of the
remaining quarters was designated as an untreated control,
while the fourth quarter was disregarded. There was no
evidence of irritation in any of the quarters regardless of
treatment and there were no differences between SCC readings
post-infusion (P=0.222). Also, there were no significant
between-treatment differences in the mean SCC readings of the
four samples pre-infusion and the final two samples post-
infusion (P=0.244). 
In general, in all three experiments, control teats that were either
untreated or infused with commercial teat seal maintained normal
readings and the mean CMT values for the first three milkings
post-infusion were less than 1.5. Subsequent mean SCC values
did not exceed 400,000 ml-1 in any of the control samples. These
data indicated that the teat seal was non-irritant, as reflected by
similar cellular responses in the treated quarters and in the
untreated quarters. SCC and CMT values for the quarters
infused with sodium cloxacillin were similar to those of the
untreated quarters. 
Taken together, these results indicate that while the infusion of
seal containing either the lacticin product or TYG-derived
lacticin powders caused a rise in SCC, this effect was temporary
and without any long-term negative effects on the cows. The
solubilised lacticin preparation derived from TYG (TYG-L) did
not cause irritation, suggesting that the irritation observed with
teat seal containing lacticin powder derived from TYG or DWP
may have been associated with the particulate nature of the
powder preparations rather than with lacticin or some other
substance from the processed fermentate. This finding is similar
to those in some of the early in vivo mastitis studies with
another bacteriocin, nisin (Taylor et al., 1949), in which
relatively large particle sizes contributed to tissue irritation. The
irritation was short-lived in all cases and, in fact, it may enhance
the efficacy of teat seal plus lacticin by acting as an
immunostimulant. Alternative substrates such as whey permeate
are currently being evaluated for suitability for lacticin
production.
Overall perspectives: a dairy solution to a dairy
problem?
Although lacticin had been shown to be ineffective against
Gram-negative bacteria (Rea and Cogan, 1994; Ryan et al.,
1998), evidence that it is bactericidal to a broad range of Gram-
positive bacteria, including S. aureus, Strep. uberis and Strep.
dysgalactiae, prompted investigations to determine whether or
not a formulation containing lacticin plus teat seal would
provide more efficient dry cow therapy.
Gram-positive bacteria, particularly S. aureus, cause major
problems in mastitis control, particularly in herds where teat
disinfection is rarely or never used and in autumn-calving herds,
where the cows are at pasture at drying-off. The animal studies
reviewed in this paper indicate that teat seal plus lacticin DWP
provided good protection against colonisation of the udder by
streptococci. While it did not achieve the same level of success
against experimental infection with S. aureus, the results were
promising; for instance, 18h after infusion of a challenge dose of
that pathogen into the teat ducts of lactating cows, there were
fewer pathogens in milk from quarters that had been infused
with seal plus lacticin DWP than in milk from those infused
with seal only. Thus, the DWP-derived lacticin-enriched powder
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was capable of reducing the numbers of S. aureus being shed by
the udder. 
If the hygienic conditions are substandard and the technique of
intramammary infusion at drying off is poor, the lacticin 3147
will not protect the udder from invasion by Gram-negative
bacteria. However, in those circumstances, the short-lived rise in
SCC induced by infusion of the teat seal plus lacticin DWP
formulation might be beneficial, as a moderate stimulation of the
immune system may enhance the innate defences of the udder to
those microbes. It can be very difficult to assess the relative
importance of an antimicrobial action versus the immune
stimulatory effects of preparations that are irritants; in practice,
the protective effect is probably a result of both activities. It
remains a possibility that the irritant action of the infusate might
exercise sufficient immunostimulatory effects to prevent Gram-
negative bacteria from inducing mastitis in dry cows.
The current problems worldwide regarding antibiotic resistance
and the debate regarding the prophylactic use of antibiotics in
animals dictates that novel remedies and management practices
are required to offset problems with bovine mastitis. The use of
antibiotics for prophylactic purposes may be restricted in the
future; for this reason, there is a growing need for effective
natural alternatives. A non-antibiotic anti-mastitis dry cow
formulation containing lacticin combined with an
intramammary teat seal has considerable potential for the
prevention of mastitis in dry cows.
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